[1] ROSENBERG A Z,NAICKER S,WINKLER C A,et al.HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment[J].Nat Rev Nephrol,2015,11(3):150-160.
[2] KUDOSE S,SANTORIELLO D,BOMBACK A S,et al.The spectrum of kidney biopsy findings in HIV-infected patients in the modern era[J].Kidney Int,2020, 97(5):1006-1016.
[3] MARRAS D,BRUGGEMAN L A,GAO F,et al.Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV associated nephropathy[J].Nat Med,2002,8(5):522-526.
[4] ROSENSTIEL P E,GRUOSSO T,LETOURNEAU A M,et al.HIV-1Vpr inhibits cytokinesis in human proximal tubule cells[J].Kidney Int,2008,74(8):1049-1058.
[5] ALSHARHAN L,BECK L H Jr.Membranous nephropathy: core curriculum[J].Am J Kidney Dis,2021,7(3):440-453.
[6] CHARU V,ANDEEN N,WALAVALKAR V,et al.Membranous nephropathy in patients with HIV: a report of 11 cases[J].BMC Nephrol,2020,21(1):401-408.
[7] NIKOLOPOULOU A,TEIXEIRA C,COOK H T,et al.Membranous nephropathy associated with viral infection[J].Clin Kidney J,2020,14(3):876-883.
[8] 马杰,文煜冰,郑可,等.八例HIV感染合并肾脏损害患者的临床病历分析[J].中华肾脏病杂志,2013,29(10):748-753.
[9] 乐晓琴,宋炜,沈银忠,等.人类免疫缺陷病毒感染合并肾脏疾病患者的肾脏病理和临床特征[J].中华传染病杂志,2020,38(4):221-224.
[10] MA J,ZHENG Q,ZHANG H,et al.The spectrum of kidney biopsy findings in Chinese HIV-infected patients[J].HIV Med,2022,23(Suppl 1):23-31.
[11] SELDA A,BILGUI M,MESUT Y,et al.A patient with HIV infection presenting with diffuse membranous glomerulonephritis in a country with a low HIV prevalence-remarkable remission with therapy[J].J Infect Public Health,2012,5(2):207-210.
[12] BOBART S A,DE VRIESE A S,PAWAR A S,et al.Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies[J].Kidney Int,2019,95(2):429-438.
[13] DAI H,ZHANG H,HE Y.Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis[J].Sci Rep,2015,5:8803-8812.
[14] SWANEPOEL C R,ATTA M G,D'AGATI V D,et al.Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes(KDIGO) Controversies Conference[J].Kidney Int,2018,93(3):545-559.
[15] SCHUTTE-NUTGEN K,THOLKING G,SUWELACK B,et al.Tacrolimus-pharmacokinetic considerations for clinicians[J].Curr Drug Metab,2018,19(4):342-350. |